Spineart reached the milestone of 100,000 Ti-LIFE Technology cages sold worldwide, supporting surgeons, patients and hospitals in more than 60 global markets.
Launched in 2016, Spineart’s Ti-LIFE Technology is based on a proprietary algorithm associated with an additive manufacturing process. Ti-LIFE is applied across a range of Spineart’s surgical implants, including posterior, lateral and cervical cages – hollow interbody devices used in spinal fusion surgeries. These cages act as a space holder between the vertebrae, helping to decompress the spinal cord and nerve root.
Ti-LIFE’s micro-porous structure closely mimics the architecture of the natural trabecular bone and is designed to promote osseous in-growth and cell colonization once implanted. Cages featuring the Ti-LIFE Technology have been shown to outperform other materials, demonstrating early and robust osseointegration without any bone graft or additive osteoinductive agents in just eight weeks.
“Since its launch in 2016, Spineart’s Ti-Life Technology has contributed significantly to setting a new benchmark in spinal fusion surgery around the world,” remarked Jerome Trividic, Chief Executive Officer at Spineart. “As we progress towards the 20-year anniversary of the founding of our company, this latest milestone reflects our unwavering commitment to transforming spine surgery and improving patient lives, as well as Ti-LIFE’s excellent surgical track record.”
“Surpassing the 100,000 sales milestone for our Ti-LIFE Technology cages is a powerful demonstration of our strong growth to date as well as our future potential. Thank you to our team, investors, partners, surgeons and customers, each of whom have worked alongside us to reach this goal,” added Alessia Erlingher, Chief Commercial Officer at Spineart.
Spineart reached the milestone of 100,000 Ti-LIFE Technology cages sold worldwide, supporting surgeons, patients and hospitals in more than 60 global markets.
Launched in 2016, Spineart’s Ti-LIFE Technology is based on a proprietary algorithm associated with an additive manufacturing process. Ti-LIFE is applied across a range of Spineart’s...
Spineart reached the milestone of 100,000 Ti-LIFE Technology cages sold worldwide, supporting surgeons, patients and hospitals in more than 60 global markets.
Launched in 2016, Spineart’s Ti-LIFE Technology is based on a proprietary algorithm associated with an additive manufacturing process. Ti-LIFE is applied across a range of Spineart’s surgical implants, including posterior, lateral and cervical cages – hollow interbody devices used in spinal fusion surgeries. These cages act as a space holder between the vertebrae, helping to decompress the spinal cord and nerve root.
Ti-LIFE’s micro-porous structure closely mimics the architecture of the natural trabecular bone and is designed to promote osseous in-growth and cell colonization once implanted. Cages featuring the Ti-LIFE Technology have been shown to outperform other materials, demonstrating early and robust osseointegration without any bone graft or additive osteoinductive agents in just eight weeks.
“Since its launch in 2016, Spineart’s Ti-Life Technology has contributed significantly to setting a new benchmark in spinal fusion surgery around the world,” remarked Jerome Trividic, Chief Executive Officer at Spineart. “As we progress towards the 20-year anniversary of the founding of our company, this latest milestone reflects our unwavering commitment to transforming spine surgery and improving patient lives, as well as Ti-LIFE’s excellent surgical track record.”
“Surpassing the 100,000 sales milestone for our Ti-LIFE Technology cages is a powerful demonstration of our strong growth to date as well as our future potential. Thank you to our team, investors, partners, surgeons and customers, each of whom have worked alongside us to reach this goal,” added Alessia Erlingher, Chief Commercial Officer at Spineart.
Copy to clipboard 
